Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 25 mg - 103 EUR
  • 100 mg - 309 EUR
  • 250 mg - 618 EUR

Vandetanib

Vandetanib is a tyrosine kinase inhibitor that targets the VEGFR (IC50 = 40 nM) and EGFR (IC50 = 500 nM) receptors. It is a potent in vitro inhibitor of VEGFA-stimulated endothelial cell proliferation (IC50 = 60 nM) and has been demonstrated to selectively inhibit VEGF signaling in vivo in a growth factor-induced hypotension rat model.

catalogue number: V078
synonyms: Zactima, ZD6474
CAS: 443913-73-3
MW: 475.35 g/mol

References
J Med Chem. 2002 Mar 14;45(6):1300-12. PMID: 11881999
Cancer Res. 2002 Aug 15;62(16):4645-55. PMID: 12183421

Prices
  • 25 mg - 88 EUR
  • 100 mg - 264 EUR
  • 250 mg - 528 EUR

Vatalanib (dihydrochloride)

Vatalanib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, active in the submicromolar range. It also inhibits other class III kinases, such as the platelet-derived growth factor (PDGF) receptor beta tyrosine kinase, c-Kit, and c-Fms, but at higher concentrations. It is not active against kinases from other receptor families, such as epidermal growth factor receptor, fibroblast growth factor receptor-1, c-Met, and Tie-2, or intracellular kinases such as c-Src, c-Abl, and protein kinase C-alpha. Vatalanib is being developed by Bayer Schering and Novartis and currently undergoes phase III clinical trials

catalogue number: V152
synonyms: CGP-79787, PTK787, ZK222584
CAS: 212141-51-0
MW: 419.73 g/mol (dihydrochloride)

References
Cancer Res. 2000 Apr 15;60(8):2178-89. PMID: 10786682
J Med Chem. 2000 Jun 15;43(12):2310-23. PMID: 10882357

Prices
  • 5 mg - 85 EUR
  • 25 mg - 199 EUR
  • 100 mg - 599 EUR

datasheet

VE-821

VE-821 was described as a potent and selective inhibitor of protein kinase ATR. The compound acts as an ATP competitor with IC50 value of 50 nM for ATR at 50 microM ATP. It exhibited no significant activity against a panel of 50 kinases. A synthetic lethal interaction between ATR and the ATM-p53 pathway was shown in cells treated with DNA-damaging agents. VE-821 significantly enhanced the sensitivity of pancreatic cancer cells to radiation. ATR inhibition by VE-821 led to suppression of radiation-induced G2/M arrest in cancer cells and reduced cancer cell survival, accompanied by increased DNA damage and inhibition of homologous recombination repair. Growth arrest induced by ATR inhibition in normal cells is reversible and VE-821 does not induce cytotoxicity in normal cells.

catalogue number: V134
synonyms: -
CAS: 1232410-49-9
MW: 368.41 g/mol

References
Cancer Biol Ther. 2012 Sep;13(11):1072-81. PMID: 22825331
Br J Cancer. 2012 Jul 10;107(2):291-9. PMID: 22713662
Nat Chem Biol. 2011 Apr 13;7(7):428-30. PMID: 21490603
7th NCRI Cancer Conference, 6-9 November 2011, Liverpool, UK Meeting abstract LB64

Prices
  • 5 mg - 55 EUR
  • 25 mg - 220 EUR
  • 100 mg - 660 EUR

Vemurafenib

Vemurafenib is a BRAF inhibitor approved for the treatment of late-stage melanoma and for the treatment of adult patients with BRAF V600E unresectable or metastatic melanoma. In preclinical models, vemurafenib inhibited the growth of BRAF V600E-positive melanoma cell lines both in vitro and in vivo. Purified kinase assays have demonstrated that PLX-4032 and its related analogs are highly potent inhibitors of B-Raf activity, with 3-fold selectivity for the V600E mutation over the wild-type kinase.

catalogue number: V156
synonyms: PLX4032, RG7204, RO5185426, Zelboraf
CAS: 918504-65-1
MW: 489.92 g/mol

References
Curr Opin Investig Drugs. 2010 Jun;11(6):699-706. PMID: 20496265
Cancer Res. 2010 Jul 1;70(13):5518-27. PMID: 20551065

Prices
  • 5 mg - 120 EUR
  • 25 mg - 480 EUR
  • 100 mg - 1440 EUR

Venetoclax

Venetoclax (ABT-199) is a selective small molecule inhibitor of Bcl-2. It mimics BH3-only proteins (the native ligands of Bcl-2 and apoptosis activators) and binds to the hydrophobic groove of Bcl-2, thereby repressing Bcl-2 activity and restoring apoptosis in cancer cells. This compound is orally available and has shown promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia (Bcl-2-dependent).

catalogue number: V172
synonyms: ABT-199, ABT199, GDC0199
CAS: 1257044-40-8
MW: 868.44 g/mol

References
Nat Med. 2013 Feb;19(2):202-8. PMID: 23291630
Leuk Lymphoma. 2013 Aug;54(8):1823-5. PMID: 23614795

Prices
  • 25 mg - 95 EUR
  • 100 mg - 285 EUR
  • 250 mg - 570 EUR

Vinblastine sulfate

Vinblastine is a vinca alkaloid that binds tubulin, thereby inhibiting the assembly of microtubules and arresting the cell cycle during mitosis. It has been used to treat Hodgkin's disease, non-Hodgkin's lymphoma, Kaposi's sarcoma, T-cell lymphoma, choriocarcinoma, and testicular, breast, lung, head and neck, and bladder cancers. It is also used in the treatment of histiocytosis and idiopathic thrombocytopenia purpura.

catalogue number: V131
synonyms: vincaleukoblastine, alkaban, velban
CAS: 143-67-9
MW: 909.05 g/mol (sulfate)

References
Chem Rec. 2010 Apr;10(2):101-18. PMID: 20394103
Nat Rev Drug Discov. 2010 Oct;9(10):790-803. PMID: 20885410

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

Vincristine sulfate

Vincristine destabilizes microtubules and thereby interferes with the dynamics of microtubules during cell division, blocking the progression of mitosis and triggering apoptosis.

catalogue number: V087
synonyms: leurocristine, Oncovin, Vincrex
CAS: 2068-78-2
MW: 923.04 g/mol

References
Biochemistry. 1996 May 28;35(21):6806-14. PMID: 8639632
Methods Cell Biol. 2010;95:373-90. PMID: 20466145

Prices
  • 1 mg - on request
  • 10 mg - on request
  • 100 mg - on request

Vindesine

Vindesine is a vinca alkaloid that is related to vincristine that also binds to tubulin. Its spectrum of antitumoral activity is similar to that of vincristine, but with milder experimental neurotoxicity.

catalogue number: V132
synonyms: eldisine, deacetyl vinblastine carboxamide, desacetylvinblastine amide
CAS: 59917-39-4
MW: 753.93 g/mol

References
Recent Results Cancer Res. 1980;74:91-7. PMID: 7003662
Br J Cancer. 2000 Jun;82(12):1907-13. PMID: 10864196
Crit Rev Oncol Hematol. 2001 Dec;40(3):251-63. PMID: 11738948
Nat Rev Drug Discov. 2010 Oct;9(10):790-803. PMID: 20885410

Prices
  • 5 mg - 110 EUR
  • 25 mg - 310 EUR
  • 100 mg - 930 EUR

Vinflunine ditartrate

Vinflunine destabilizes microtubules with an IC50 of 18.8 nM and interferes with the dynamics of microtubules during cell division. It blocks the progression of mitosis and triggers apoptosis.

catalogue number: V088
synonyms: Javlor
CAS: 194468-36-5
MW: 1117.10 g/mol

References
Biochem Pharmacol. 1998 Mar 1;55(5):635-48.PMID: 9515574
Methods Cell Biol. 2010;95:373-90. PMID: 20466145

Prices
  • 5 mg - on request
  • 25 mg - on request
  • 100 mg - on request

Vinorelbine

Vinorelbine is a third-generation semi-synthetic vinca alkaloid that is related to vincristine but exhibits significantly lower toxicity towards neuronal tissue and greater cytotoxic activity than the older compounds in this class. It binds to tubulin and thereby inhibits microtubule assembly, arresting the cell cycle during mitosis. Vinorelbine has been approved for the treatment of non-small cell lung cancer and breast cancer.

catalogue number: V133
synonyms: Navelbine
CAS: 71486-22-1
MW: 778.93 g/mol

References
Cancer Invest. 1997;15(5):475-90. PMID: 9316630
Nat Rev Drug Discov. 2010 Oct;9(10):790-803. PMID: 20885410

Prices
  • 25 mg - 24 EUR
  • 100 mg - 70 EUR
  • 250 mg - 140 EUR

Vorinostat (SAHA)

Vorinostat is an inhibitor of histone deacetylases (HDAC). It is primarily used to correct aberrant balances between acetylated and deacetylated histones, the proteins that control chromatin structure and organization. It has been approved for the treatment of cutaneous T-cell lymphoma.

catalogue number: V079
synonyms: SAHA, suberoylanilide hydroxamic acid, Zolinza, MK-0683
CAS: 149647-78-9
MW: 264.32 g/mol

References
J Hematol Oncol. 2009 Jul 27;2:31. PMID: 19635146
Mol Cancer. 2010 Mar 4;9:49. PMID: 20202195
Am J Health Syst Pharm. 2010 May 15;67(10):793-7. PMID: 20479100

Prices
  • 25 mg - 85 EUR
  • 100 mg - 255 EUR
  • 250 mg - 510 EUR

VX-680

VX-680 is a highly potent and selective small-molecule inhibitor of Aurora kinases, with Ki values of 0.6, 18 and 4.6 nM against Aurora A, B and C, respectively. In addition, it has activity against BCR-ABL, including the T315I BCR-ABL mutant. VX-680 blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types both in vitro and in vivo.

catalogue number: V080
synonyms: MK-0457, Tozasertib
CAS: 639089-54-6
MW: 464.59 g/mol

References
Nat Med. 2004 Mar;10(3):262-7. PMID: 14981513
Blood. 2007 Jan 15;109(2):500-2. PMID: 16990603
Cancer Lett. 2007 Jun 28;251(2):323-9. PMID: 17240048

Prices
  • 5 mg - 62 EUR
  • 25 mg - 248 EUR
  • 100 mg - 744 EUR

VX-702

VX-702 is a second-generation, orally active p38 MAP kinase inhibitor, developed for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in patients with rheumatoid arthritis.

catalogue number: V153
synonyms: -
CAS: 745833-23-2
MW: 404.32 g/mol

References
Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. PMID: 17117592